UPM Institutional Repository

Efficiency of newly formulated camptothecin with β-cyclodextrin-EDTA-Fe3O4 nanoparticle-conjugated nanocarriers as an anti-colon cancer (HT29) drug


Krishnan, Poorani and Rajan, Mariappan and Kumari, Sharmilah and Syed, Sakinah and Priya, Sivan Padma and Fatin Amira and Danjuma, Lawal and Mok, Pooi Ling and Fakurazi, Sharida and Arulselvan, Palanisamy and Higuchi, Akon and Arumugam, Ramitha and Alarfaj, Abdullah A. and Munusamy, Murugan A. and Hamat, Rukman Awang and Benelli, Giovanni and Murugan, Kadarkarai and Kumar, S. Suresh (2017) Efficiency of newly formulated camptothecin with β-cyclodextrin-EDTA-Fe3O4 nanoparticle-conjugated nanocarriers as an anti-colon cancer (HT29) drug. Scientific Reports, 7 (1). pp. 1-16. ISSN 2045-2322


Camptothecin (CPT) is an anti-cancer drug that effectively treats various cancers, including colon cancer. However, poor solubility and other drawbacks have restricted its chemotherapeutic potential. To overcome these restrictions, CPT was encapsulated in CEF (cyclodextrin-EDTA-FE3O4), a composite nanoparticle of magnetic iron oxide (Fe3O4), and β-cyclodextrin was cross-linked with ethylenediaminetetraacetic acid (EDTA). This formulation improved CPT's solubility and bioavailability for cancer cells. The use of magnetically responsive anti-cancer formulation is highly advantageous in cancer chemotherapy. The chemical characterisation of CPT-CEF was studied here. The ability of this nano-compound to induce apoptosis in HT29 colon cancer cells and A549 lung cancer cells was evaluated. The dose-dependent cytotoxicity of CPT-CEF was shown using MTT. Propidium iodide and Annexin V staining, mitochondrial membrane depolarisation (JC-1 dye), and caspase-3 activity were assayed to detect apoptosis in CPT-CEF-treated cancer cells. Cell cycle analysis also showed G1 phase arrest, which indicated possible synergistic effects of the nano-carrier. These study results show that CPT-CEF causes a dose-dependent cell viability reduction in HT29 and A549 cells and induces apoptosis in colon cancer cells via caspase-3 activation. These data strongly suggest that CPT could be used as a major nanocarrier for CPT to effectively treat colon cancer.

Download File

[img] Text
Efciency of newly formulated.pdf
Restricted to Repository staff only

Download (3MB)

Additional Metadata

Item Type: Article
Divisions: Faculty of Medicine and Health Science
Faculty of Science
DOI Number: https://doi.org/10.1038/s41598-017-09140-1
Publisher: Nature Publishing Group
Keywords: Camptothecin; β-cyclodextrin-EDTA-Fe3O4; Nanoparticle; Nanocarriers; Anti-colon cancer (HT29) drug; Anti-cancer drug
Depositing User: Nurul Ainie Mokhtar
Date Deposited: 31 Oct 2018 07:02
Last Modified: 31 Oct 2018 07:02
Altmetrics: http://www.altmetric.com/details.php?domain=psasir.upm.edu.my&doi=10.1038/s41598-017-09140-1
URI: http://psasir.upm.edu.my/id/eprint/61681
Statistic Details: View Download Statistic

Actions (login required)

View Item View Item